Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas.
Loss or mutation of p53 is thought to be an early event in the malignant transformation of many human astrocytic tumors. To better understand the role of p53 in their growth and transformation, we developed a model employing cultured neonatal astrocytes derived from mice deficient in one (p53 +/-) or both (p53 -/-) p53 alleles, comparing them with wild-type (p53 +/+) cells. Studies of in vitro and in vivo growth and transformation were performed, and flow cytometry and karyotyping were used to correlate changes in growth with genomic instability. Early-passage (EP) p53 -/- astrocytes achieved higher saturation densities and had more rapid growth than EP p53 +/- and +/+ cells. The EP p53 -/- cells were not transformed, as they were unable to grow in serum-free medium or in nude mice. With continued passaging, p53 -/- cells exhibited a multistep progression to a transformed phenotype. Late-passage p53 -/- cells achieved saturation densities 50 times higher than those of p53 +/+ cells and formed large, well-vascularized tumors in nude mice. p53 +/- astrocytes exhibited early loss of the remaining wild-type p53 allele and then evolved in a manner phenotypically similar to p53 -/- astrocytes. In marked contrast, astrocytes retaining both wild-type p53 alleles never exhibited a transformed phenotype and usually senesced after 7 to 10 passages. Dramatic alterations in ploidy and karyotype occurred and were restricted to cells deficient in wild-type p53 following repeated passaging. The results of these studies suggest that loss of wild-type p53 function promotes genomic instability, accelerated growth, and malignant transformation in astrocytes.
Yahanda
A M
AM
Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA.
Bruner
J M
JM
Donehower
L A
LA
Morrison
R S
RS
D000818:Animals; D001253:Astrocytes / Q000473:pathology*; D015139:Blotting, Southern; D002455:Cell Division / Q000187:drug effects; D002471:Cell Transformation, Neoplastic; D003433:Crosses, Genetic; D004273:DNA, Neoplasm / Q000235:genetics; D004195:Disease Models, Animal; D016222:Fibroblast Growth Factor 2 / Q000235:genetics / Q000494:pharmacology; D005434:Flow Cytometry; D005910:Glioma / Q000098:blood supply / Q000209:etiology* / Q000235:genetics / Q000473:pathology; D007150:Immunohistochemistry; D007621:Karyotyping; D051379:Mice; D008815:Mice, Inbred Strains; D008822:Mice, Transgenic; D009374:Neoplasms, Experimental; D016376:Oligonucleotides, Antisense; D016159:Tumor Suppressor Protein p53 / Q000172:deficiency*
D004273:DNA, Neoplasm; D016376:Oligonucleotides, Antisense; D016159:Tumor Suppressor Protein p53; D016222:Fibroblast Growth Factor 2